Metabolic effects of protease inhibitor therapy.
Fat redistribution (lipodystrophy) and metabolic anomalies are reported increasingly in HIV-infected patients being treated with protease inhibitors. The incidence of these side effects ranges from 5% to 75% in such patients, who often complain of spontaneous fat wasting in the face, arms, or legs, with or without central obesity. Hyperlipidemia and insulin resistance are almost always associated with lipodystrophy. We review the metabolic complications of antiretroviral therapies and discuss possible therapeutic interventions.
Infectious Disease Unit, Department of Medicine, Regional Hospital, Lugano, Switzerland.
E
E
Bernasconi
D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active; D001823:Body Composition / Q000187:drug effects; D006679:HIV Seropositivity / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000209:etiology* / Q000628:therapy; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000628:therapy; D007333:Insulin Resistance; D011480:Protease Inhibitors / Q000009:adverse effects*; D012307:Risk Factors
D019380:Anti-HIV Agents; D011480:Protease Inhibitors